Continuous maximal bronchodilatation with UMEC/VI as first line treatment for smokers at risk of developing COPD

Next Previous
Trial Profile

Continuous maximal bronchodilatation with UMEC/VI as first line treatment for smokers at risk of developing COPD

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Umeclidinium (Primary) ; Vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms The ECOS

    • Most Recent Events

    • 10 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top